Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels

American Journal of Hypertension

Volumn 28, Issue 5, 2015, Pages 664-671

  Carroll, Mairéad A ^a   Kang, Youn Jung ^a   Chander, Praveen N ^a   Stier, Charles T ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angiotensins; AT1 receptor blocker; Blood pressure; Eicosanoids; Hypertension; Kidney

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ANGIOTENSIN[1-7]; AZILSARTAN; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; ANGIOTENSIN I; ANGIOTENSIN I (1-7); BENZIMIDAZOLE DERIVATIVE; HYDROXYICOSATETRAENOIC ACID; OXADIAZOLE DERIVATIVE; PEPTIDE FRAGMENT;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG MECHANISM; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; KIDNEY INJURY; LIPID ANALYSIS; MALE; MINIPUMP; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; URINE VOLUME; ANIMAL; BLOOD; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, RENOVASCULAR; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASOCONSTRICTION;

ANGIOTENSIN I; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; MALE; OXADIAZOLES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION;

EID: 84928599758     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu201     Document Type: Article

References (44)

1. Hall JE. Historical perspective of the renin-angiotensin system. Mol Biotechnol 2003; 24:27-39.
2. Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, Jeunemaitre X, Thomas A. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am J Hypertens 2011; 24:1143-1148.
3. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011; 13:e11.
4. Becher UM, Endtmann C, Tiyerili V, Nickenig G, Werner N. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system. Curr Hypertens Rep 2011; 13:86-92.
5. Gwathmey TM, Shaltout HA, Pendergrass KD, Pirro NT, Figueroa JP, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol 2009; 296:F1484-F1493.
6. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 2010; 55:445-452.
7. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007; 25:162-174.
8. Burgelova M, Vanourkova Z, Thumova M, Dvorak P, Opocensky M, Kramer HJ, Zelizko M, Maly J, Bader M, Cervenka L. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009; 27:1988-2000.
9. Rakušan D, Burgelova M, Van?kova I, Va?ourkova Z, Huskova Z, Skaroupkova P, Mrazova I, Opo?ensky M, Kramer HJ, Netuka I, Maly J, Alenina N, Bader M, Santos RA, Cervenka L. Knockout of angiotensin 1-7 receptor Mas worsens the course of two-kidney, one-clip Goldblatt hypertension: roles of nitric oxide deficiency and enhanced vascular responsiveness to angiotensin II. Kidney Blood Press Res 2010; 33:476-488.
10. Benter IF, Yousif MH, Anim JT, Cojocel C, Diz DI. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am J Physiol Heart Circ Physiol 2006; 290:H684-H691.
11. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
12. Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension 2013; 61:417-424.
13. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011; 34:154-160.
14. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111:1806-1813.
15. Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 2009; 50(Suppl):S52-S56.
16. Williams JM, Murphy S, Burke M, Roman RJ. 20-Hydroxyeicosatetraeonic acid: A new target for the treatment of hypertension. J Cardiovasc Pharmacol 2010; 56:336-344.
17. Liclican EL, Doumad AB, Wang J, Li J, Falck JR, Stier CT Jr, Carroll MA. Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. Hypertension 2009; 54:1284-1290.
18. Wu CC, Gupta T, Garcia V, Ding Y, Schwartzman ML. 20-HETE and blood pressure regulation: clinical implications. Cardiol Rev 2014; 22:1-12.
19. Cheng J, Garcia V, Ding Y, Wu CC, Thakar K, Falck JR, Ramu E, Schwartzman ML. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2012; 32:1917-1924.
20. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 2000; 279:F544-F551.
21. Fan F, Sun CW, Maier KG, Williams JM, Pabbidi MR, Didion SP, Falck JR, Zhuo J, Roman RJ. 20-Hydroxyeicosatetraenoic acid contributes to the inhibition of K+ channel activity and vasoconstrictor response to angiotensin II in rat renal microvessels. PLoS One 2013; 8:e82482.
22. Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 2008; 21:852-859.
23. Sabban EL, Schilt N, Serova LI, Masineni SN, Stier CT Jr. Kinetics and persistence of cardiovascular and locomotor effects of immobilization stress and influence of ACTH treatment. Neuroendocrinology 2009; 89:98-108.
24. Diz DI, Baer PG, Nasjletti A. Angiotensin II-induced hypertension in the rat. Effects on the plasma concentration, renal excretion, and tissue release of prostaglandins. J Clin Invest 1983; 72:466-477.
25. Ye Y, Keyes KT, Zhang CF, Perez-Polo JR, Lin Y, Birnbaum Y. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther 2010; 24:107-120.
26. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006; 291:H2166-H2172.
27. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 2008; 13:3480-3487.
28. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30:535-541.
29. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005; 289:H2281-H2290.
30. Iwanami J, Mogi M, Tsukuda K, Wang XL, Nakaoka H, Ohshima K, Chisaka T, Bai HY, Kanno H, Min LJ, Horiuchi M. Role of angiotensinconverting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan. Hypertens Res 2014; 37:616-620.
31. Yamada K, Iyer SN, Chappell MC, Brosnihan KB, Fukuhara M, Ferrario CM. Differential response of angiotensin peptides in the urine of hypertensive animals. Regul Pept 1999; 80:57-66.
32. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111:315-320.
33. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31:699-705.
34. Benter IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269:H313-H319.
35. Ohshima K, Mogi M, Nakaoka H, Iwanami J, Min LJ, Kanno H, Tsukuda K, Chisaka T, Bai HY, Wang XL, Ogimoto A, Higaki J, Horiuchi M. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 2014; 63:e53-e59.
36. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: A new generation angiotensin II receptor blocker. J Hypertens 2011; 29:2476-2483.
37. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68:2189-2196.
38. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev 1998; 78:583-686.
39. Sigmund CD. Divergent mechanism regulating fluid intake and metabolism by the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 2012; 302:R313-R320.
40. Khan MA, Neckar J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther 2014;28:313-322.
41. Hye Khan MA, Necka? J, Haines J, Imig JD. Azilsartan improves glycemic status and reduces kidney damage in zucker diabetic fatty rats. Am J Hypertens 2014;27:1087-1095.
42. Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin-( 1-7) on vascular smooth muscle cell proliferation and migration. PLoS One 2010; 5:e12323.
43. Wu JG, Tang H, Liu ZJ, Ma ZF, Tang AL, Zhang XJ, Gao XR, Ma H. Angiotensin-(1-7) inhibits vascular remodelling in rat jugular vein grafts via reduced ERK1/2 and p38 MAPK activity. J Int Med Res 2011; 39:2158-2168.
44. Akhtar S, Yousif MH, Dhaunsi GS, Chandrasekhar B, Al-Farsi O, Benter IF. Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway. Br J Pharmacol 2012; 165:1390-1400.